Immunic (IMUX) Stock Forecast: StockMap's 2-Week Call

IMUX stock forecast: StockMap's model leans Underperform on Immunic for the two weeks after the Nov 18 close, toward IMUX trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 5 of 6 two-week windows on IMUX since Aug 21; by chance, a call on the same dates was right 60% of the time.

Immunic last closed at $7.52, +2.59% on the session.

Against the IVW growth benchmark the position is +2.57% over the forecast window.

Immunic's market cap is $119.42M as of November 18, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -36 (too close to call).

Where IMUX sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

48 daily calls for IMUX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Immunic in the 7th percentile on return on equity, where 100 is best.

Immunic is classified under Health Care / Biotechnology.

StockMap tracks Immunic as the 264th largest of the 393 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 195 Moderate Underperform, 141 Neutral, 42 Strong Underperform and 15 Moderate Outperform.

On that composite Immunic ranks 274th of 393 in the group, against a group median of -0.27.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 18, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Immunic (IMUX) — StockMap 2-week forecast & tracked accuracy